SCHEMBL3821928

SCHEMBL3821928

CCCn1c(C(C)Br)nc2ccccc2c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
CACNA2D1 P54289 7/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
PDE5A O76074 1/20 0.46
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
TSHR P16473 3/20 0.46
MAPK1 P28482 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HTT P42858 1/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
ALOX15 P16050 1/20 0.46
CASP1 P29466 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7480981 0.88 TSHR (0.54) ALDH1A1SMN1; SMN2CACNA2D1MEN1KMT2A
SCHEMBL1520755 0.84 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2CACNA2D1MEN1KMT2A
SCHEMBL6096918 0.83 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2CACNA2D1MEN1KMT2A
SCHEMBL22854493 0.83 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2CACNA2D1MEN1KMT2A
SCHEMBL15457140 0.83 CACNA2D1 (0.48) ALDH1A1SMN1; SMN2CACNA2D1MEN1KMT2A
SCHEMBL3816839 0.81 KDM4E (0.57) ALDH1A1SMN1; SMN2CACNA2D1KDM4EUSP2
SCHEMBL12963486 0.78 MEN1 (0.73) ALDH1A1SMN1; SMN2MEN1KMT2APDE5A
SCHEMBL24340312 0.77 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2MEN1KMT2APDE5A
SCHEMBL3821434 0.77 TSHR (0.59) ALDH1A1SMN1; SMN2MEN1KMT2APDE5A
SCHEMBL22854475 0.77 KDM4E (0.44) ALDH1A1SMN1; SMN2KMT2ATSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 US disclosed
EP-1646615-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2009-08-26 EP disclosed
EP-1646615-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2009-08-26 EP disclosed
EP-1646615-A1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2006-04-19 EP disclosed
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2005-03-17 US disclosed
WO-2004111014-A1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters CFTR, ABCB1, ABCC2 ALDH1A1 1892/4885SMN1; SMN2 4840/4885CACNA2D1 3450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.